NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $48,745 | -91.0% | 84,744 | -15.3% | 0.00% | -100.0% |
Q1 2022 | $539,000 | +123.7% | 100,000 | +861.4% | 0.01% | +133.3% |
Q2 2020 | $241,000 | -82.0% | 10,401 | -74.5% | 0.00% | -87.0% |
Q4 2018 | $1,341,000 | +512.3% | 40,755 | +1036.2% | 0.02% | +1050.0% |
Q3 2018 | $219,000 | -26.3% | 3,587 | -83.4% | 0.00% | -60.0% |
Q1 2016 | $297,000 | – | 21,600 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |